Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018:38:61-65.
doi: 10.1007/8904_2017_31. Epub 2017 May 25.

GM2 Activator Deficiency Caused by a Homozygous Exon 2 Deletion in GM2A

Patricia L Hall  1   2 , Regina Laine  3 , John J Alexander  4   5 , Arunkanth Ankala  4   5 , Lisa A Teot  6 , Hart G W Lidov  7   8 , Irina Anselm  9   10
Affiliations

GM2 Activator Deficiency Caused by a Homozygous Exon 2 Deletion in GM2A

Patricia L Hall et al. JIMD Rep. 2018.

Abstract

GM2 activator (GM2A) deficiency (OMIM 613109) is a rare lysosomal storage disorder, with onset typically in infancy or early childhood. Clinically, it is almost indistinguishable from Tay-Sachs disease (OMIM 272800) or Sandhoff disease (OMIM 268800); however, traditionally available biochemical screening tests will most likely reveal normal results. We report a 2-year-old male with initially normal development until the age of 9 months, when he presented with developmental delay and regression. Workup at that time was unrevealing; at 15 months, he had abnormal brain MRI findings and a cherry red spot on ophthalmological examination. Family history and all laboratory studies were uninformative. The combination of a cherry red spot and developmental regression was strongly suggestive of a lysosomal storage disorder. Sequence analysis of GM2A did not reveal any pathogenic variants; however, exon 2 of GM2A could not be amplified by PCR, raising suspicion for a large, homozygous deletion. Subsequent copy number analysis confirmed a homozygous deletion of exon 2 in GM2A. This is the first reported case of GM2A deficiency being caused by a whole exon deletion. We describe previously unreported electron microscopy findings in this disease, thus expanding the clinical and variant spectrum for GM2 activator deficiency. These findings demonstrate the increased degree of suspicion required for diagnosis of this rare disorder. Brief Summary: This case of GM2 activator deficiency was caused by a homozygous deletion in GM2A, demonstrating the need to include exon level copy number analysis in any workup to fully exclude this disorder.

Keywords: Cherry red spot; Copy number analysis; Electron microscopy; GM2 activator deficiency; GM2A; Lysosomal storage disorder.

PubMed Disclaimer

Conflict of interest statement

Patricia Hall is employed by Emory University and is a laboratory director at EGL Genetic Diagnostics, LLC, a clinical genetics laboratory which performs testing described in this paper.

John Alexander is employed by Emory University and is a laboratory director at EGL Genetic Diagnostics, LLC, a clinical genetics laboratory which performs testing described in this paper.

Arun Ankala is employed by Emory University and is a laboratory director at EGL Genetic Diagnostics, LLC, a clinical genetics laboratory which performs testing described in this paper.

Regina Laine, Hart Lidov, Lisa Teot, and Irina Anselm declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
(a) Electron microscopy from a skin biopsy of our patient. Axons with degenerative changes containing membrane bound debris (solid white arrows), areas of axonal retraction, and Schwann cell cytoplasm also filled with membrane bound debris (white outline arrows). Original magnification 6000x. (b) Electron microscopy from a skin biopsy of our patient. Cell with “zebra bodies” (solid white arrows), myelinosomes (white star), and granular membrane bound vesicles (outline arrow). This may represent a Schwann cell but definite myelin is not seen, so identification is uncertain. Original magnification 6000x
Fig. 2
Fig. 2
Exon 2 deletion in GM2A. (a) Schematic representation of the deletion detected in the GM2A gene. The deleted region is represented with dotted lines whereas the intact region is represented with solid lines. The downward arrows indicate the breakpoints of the deletion. Also indicated are the intact (Black) and deleted (Gray) bases flanking each breakpoint. (b) Sequence alignment showing microhomology at the breakpoint junction. Patient sequence across the deletion breakpoint, as obtained by Sanger sequencing, was aligned to the reference sequences from both the 5′ breakpoint and the 3′ breakpoint. As shown in the figure, a 7 bp sequence, “AGCTGGG” was detected on either sides of the deletion. The deletion has been refined to be 6,142 bp long extending from and including chr5:g.150,636,648 to chr5:g.150,642,789. These results, together with the failure of PCR amplification of exon 2, confirm a homozygous deletion of exon 2 of the GM2A gene in this individual. Ref. reference, Seq sequence, Bkpt breakpoint
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Chen JM, Cooper DN, Ferec C, Kehrer-Sawatzki H, Patrinos GP. Genomic rearrangements in inherited disease and cancer. Semin Cancer Biol. 2010;20:222–233. doi: 10.1016/j.semcancer.2010.05.007. - DOI - PubMed
    1. Hall P, Minnich S, Teigen C, Raymond K. Diagnosing lysosomal storage disorders: the GM2 gangliosidoses. Curr Protoc Hum Genet. 2014;83:17.16.11–17.16.18. - PubMed
    1. Lee JA, Carvalho CM, Lupski JR. A DNA replication mechanism for generating nonrecurrent rearrangements associated with genomic disorders. Cell. 2007;131:1235–1247. doi: 10.1016/j.cell.2007.11.037. - DOI - PubMed
    1. Renaud D, Brodsky M. GM2-gangliosidosis, AB variant: clinical, ophthalmological, MRI, and molecular findings. JIMD Rep. 2015;25:83–86. doi: 10.1007/8904_2015_469. - DOI - PMC - PubMed
    1. Sakuraba H, Itoh K, Shimmoto M, et al. GM2 gangliosidosis AB variant: clinical and biochemical studies of a Japanese patient. Neurology. 1999;52:372–377. doi: 10.1212/WNL.52.2.372. - DOI - PubMed

LinkOut - more resources